Scholarlink

Purpose <p>This article describes a&#xa0;regional study performed in patients with bone metastases from prostate cancer hypothesizing that intensified radiotherapy (metastases directed and prostate directed) may result in longer overall survival.</p> Methods <p>A&#xa0;retrospective study of 246 consecutive male patients who received 347 courses of radiotherapy in the time period 2011–2025 was performed. Patients were stratified into three cohorts spanning 5‑year intervals (2011–2015, 2016–2020, 2021–2025). Survival was analyzed in allcomers and separately in patients without visceral metastases treated within the first year after diagnosis (<i>n</i> = 119).</p> Results <p>Median overall survival was shortest in the earliest phase of the study (2011–15). The two recent cohorts had similar survival. Outpatients with high performance status irradiated early after diagnosis and to all known sites of disease experienced superior survival. In the subgroup of 119 patients, simultaneous prostate radiotherapy prolonged survival (numerically better than no prostate RT, median 40&#xa0;vs.&#xa0;26&#xa0;months, 5‑year rate 47&#xa0;vs.&#xa0;18%, <i>p</i> = 0.11). The impact of bone radiotherapy dose (dichotomized &lt; 3 Gy × 13 or its biological equivalent vs. higher doses) was significant (if synchronous metastases, 5‑year rate 64&#xa0;vs.&#xa0;17%, <i>p</i> = 0.026; if metachronous metastases, 5‑year rate 48&#xa0;vs.&#xa0;8%, <i>p</i> &lt; 0.001). Bone dose remained significant in multivariate analyses, together with clinical baseline parameters.</p> Conclusion <p>In our healthcare region, outcomes largely resemble those of prospective trials. Comprehensive radiotherapy to the prostate and bone oligometastases plus guideline-based systemic therapy resulted in favorable 5‑year survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Individualized radiotherapy of bone metastases from prostate cancer: time trends and 5-year survival results

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Carsten Nieder,
  • Luka Stanisavljevic,
  • Ellinor C. Haukland,
  • Bård Mannsåker,
  • Bence Fajth,
  • Astrid Dalhaug

摘要

Purpose

This article describes a regional study performed in patients with bone metastases from prostate cancer hypothesizing that intensified radiotherapy (metastases directed and prostate directed) may result in longer overall survival.

Methods

A retrospective study of 246 consecutive male patients who received 347 courses of radiotherapy in the time period 2011–2025 was performed. Patients were stratified into three cohorts spanning 5‑year intervals (2011–2015, 2016–2020, 2021–2025). Survival was analyzed in allcomers and separately in patients without visceral metastases treated within the first year after diagnosis (n = 119).

Results

Median overall survival was shortest in the earliest phase of the study (2011–15). The two recent cohorts had similar survival. Outpatients with high performance status irradiated early after diagnosis and to all known sites of disease experienced superior survival. In the subgroup of 119 patients, simultaneous prostate radiotherapy prolonged survival (numerically better than no prostate RT, median 40 vs. 26 months, 5‑year rate 47 vs. 18%, p = 0.11). The impact of bone radiotherapy dose (dichotomized < 3 Gy × 13 or its biological equivalent vs. higher doses) was significant (if synchronous metastases, 5‑year rate 64 vs. 17%, p = 0.026; if metachronous metastases, 5‑year rate 48 vs. 8%, p < 0.001). Bone dose remained significant in multivariate analyses, together with clinical baseline parameters.

Conclusion

In our healthcare region, outcomes largely resemble those of prospective trials. Comprehensive radiotherapy to the prostate and bone oligometastases plus guideline-based systemic therapy resulted in favorable 5‑year survival.